{
    "clinical_study": {
        "@rank": "119315", 
        "arm_group": [
            {
                "arm_group_label": "standard medication", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic"
            }, 
            {
                "arm_group_label": "renal denervation", 
                "arm_group_type": "Experimental", 
                "description": "Allegro Renal Denervation System (AngioCare)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of ALLEGRO-HTN trial is to evaluate the safety and effectiveness of renal\n      denervation in subjects with resistant hypertension by using Allegro renal denervation\n      system"
        }, 
        "brief_title": "Renal Denervation by Allegro System in Patients With Resistant Hypertension", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Denervation", 
            "Resistant Hypertension", 
            "Standard Medication"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 - 65 years at time of randomization\n\n          -  Stable medication regimen including 3 or more antihypertensive medications of\n             different classes, including a diuretic (with no changes for a minimum of 4 weeks\n             prior to screening) and no expected changes for at least 6 months\n\n          -  1) Office SBP and/or DBP \u2265160/100 mm Hg ( \u2265 150/95 mmHg for type II diabetic\n             patients) , 2) ABPM 24 hour average SBP and/or DBP \u2265140 and/or 90 mmHg\n\n          -  Main renal arteries with \u22654 mm diameter or with \u226520 mm treatable length (by visual\n             estimation)\n\n          -  eGFR\u226545 mL/min/1.73 m2\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes mellitus\n\n          -  Secondary hypertension\n\n          -  Has an implantable cardioverter defibrillator (ICD) or pacemaker\n\n          -  Myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular\n             accident within 6 months of the screening period\n\n          -  Intravascular thrombosis or unstable atherosclerotic plaques\n\n          -  Has hemodynamically significant valvular heart disease\n\n          -  Pregnant, nursing, or planning to be pregnant\n\n          -  Any serious medical condition that may adversely affect the safety of the participant\n             or the study\n\n          -  Currently enrolled in another investigational drug or device trial\n\n        Angiographic Exclusion Criteria:\n\n          -  Renal artery stenosis (\u226550%) or renal artery aneurysm in either renal artery\n\n          -  History of prior renal artery intervention including balloon angioplasty or stenting\n\n          -  Multiple renal arteries where the main renal artery is estimated to supply <75% of\n             the kidney\n\n          -  Main renal arteries with <4 mm diameter or with <20 mm treatable length (by visual\n             estimation)\n\n          -  Renal artery abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874470", 
            "org_study_id": "Allegro-HTN"
        }, 
        "intervention": [
            {
                "arm_group_label": "renal denervation", 
                "intervention_name": "renal denervation", 
                "intervention_type": "Device", 
                "other_name": "Allegro Renal Denervation System (AngioCare)"
            }, 
            {
                "arm_group_label": [
                    "standard medication", 
                    "renal denervation"
                ], 
                "intervention_name": "standard medication", 
                "intervention_type": "Other", 
                "other_name": "Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antihypertensive Agents", 
                "Diuretics", 
                "Frovatriptan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "jxj103@hotmail.com", 
                "last_name": "Xiongjing Jiang"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Fuwai hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Renal Denervation by Allegro System in Patients With Resistant Hypertension", 
        "overall_contact": {
            "email": "jxj103@hotmail.com", 
            "last_name": "Xiongjing Jiang"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in office-based systolic blood pressure (SBP) from baseline to 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in average 24-hour SBP by ambulatory blood pressure monitoring (ABPM) from baseline to 6 months", 
                "measure": "Change in average 24-hour SBP by ambulatory blood pressure monitoring (ABPM) from baseline to 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "\u2022 The incidence of major adverse events (MAE) at 1 month postrandomization", 
                "safety_issue": "Yes", 
                "time_frame": "1-month post randomization"
            }, 
            {
                "measure": "Office SBP and DBP at 1, 3, 6 months postrandomization", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "\u2022 Patient-recorded home systolic blood pressure at 1, 3, 6 months postrandomization", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "\u2022 MAE at 6-month post-randomization, including new renal artery stenosis >60%", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "source": "Shanghai AngioCare Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai AngioCare Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}